REVIEW ON BIOEQUIVALENCE STUDY AND BIO ANALYTICAL METHOD DEVELOPMENT OF ANTIARTHRITIC DRUGS USING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

Nishanth R.*, Tamilselvi N., Gopalasatheeskumar K. and Henna P. Raphy

ABSTRACT

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease predominantly affecting the joints and periarticular tissue. Several drugs such as parcetamol, opiates, Diproqualone, prednisone, prednisolone, methyl prednisolone, Methotrexate, Leflunomide, Hydroxychloroquine, chloroquine, cyclosporine, sulfasalazine, gold salts, Etanercept, infliximab, adalimumab, golimumab, anakinra, cetrolizumab, rituximab, abatecept. Bioavailability, bioequivalence and therapeutic drug monitoring studies have received major attention from the pharmaceutical industry, health authorities and clinic. These studies are performed to evaluate the safety and efficacy of a genetic structure. Which studies as well as drug product development studies require rapid, simple, sensitive and reliable bioanalytical methods to monitoring the target drug in human plasma sample. Several analytical methods have been developed to analyse drugs in plasma for pharmacokinetic and clinical trials. Current review is focused on bioanalytical method development for antiarthritic drugs using HPLC analysis.

Keywords: Arthritis, pharmacokinetic, diclofenac, antiinflamatory, NSAID, HPLC-UV.